| Literature DB >> 34935192 |
María Marta Buján1, Cristian Sánchez La Rosa2, María Laura Galluzzo Mutti3, Jorge Braier2, Eli L Diamond4.
Abstract
Progressive nodular histiocytosis is a rare variant of non-Langerhans cell histiocytosis that affects the skin and mucous membranes and displays a progressive clinical course and poor response to treatment. We describe a case of severe progressive nodular histiocytosis harboring a KRAS p.G12S mutation in a 9-year-old boy, refractory to chemotherapy, who was successfully treated with the MEK inhibitor cobimetinib. This is the first report of the use of MEK inhibition for this histiocytosis subtype in a pediatric patient.Entities:
Keywords: cobimetinib; non-Langerhans histiocytosis; progressive nodular histiocytosis
Mesh:
Substances:
Year: 2021 PMID: 34935192 PMCID: PMC8819602 DOI: 10.1111/pde.14887
Source DB: PubMed Journal: Pediatr Dermatol ISSN: 0736-8046 Impact factor: 1.588